人类免疫缺陷病毒感染者非酒精性脂肪性肝病专家小组综述
非酒精性脂肪性肝病(NAFLD)影响普通人群25%的成人,在人类免疫缺陷病毒感染者(PWH)中20%至63%有非酒精性脂肪性肝炎(NASH),14%至63%有NASH伴纤维化。本文综述PWH中NAFLD的流行病学、病理生理、诊断和管理现状,并指出研究重点。
要点
- PWH中20%至63%有NASH,14%至63%有NASH伴纤维化。
- NAFLD是心血管疾病、糖尿病和全因死亡的独立危险因素。
- PWH中慢性肝病是非HIV相关死亡的第二大原因。
核心结论
- PWH中NAFLD的诊断策略、危险因素和治疗尚知之甚少,本文识别了流行病学、病理生理、诊断和管理方面的知识缺口并突出研究重点。
研究设计与样本
- 专家小组综述,检索并汇总PWH中NAFLD的现有数据。
主要发现
- NAFLD影响普通人群25%的成人,疾病谱从脂肪变到NASH再到终末期肝病。
- PWH中20%至63%有NASH,14%至63%有NASH伴纤维化。
- PWH中慢性肝病是非HIV相关死亡的第二大原因。
- NAFLD是心血管疾病、糖尿病和全因死亡的独立危险因素,NASH肝硬化是肝移植的常见指征。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Nonalcoholic fatty liver disease (NAFLD) affects 25% of adults in the general population and is a disease spectrum ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease. NAFLD is an independent risk factor for cardiovascular disease, diabetes mellitus, and all-cause mortality, and NASH cirrhosis is a frequent indication for liver transplantation. In persons with human immunodeficiency virus (PWH), chronic liver disease is the second leading cause of non-human immunodeficiency virus-related mortality. Between 20% and 63% of PWH have NASH, and 14% to 63% have NASH with fibrosis. However, little is known about the optimal diagnostic strategies, risk factors for, and treatment of NAFLD in PWH. Here, we review current data on and identify knowledge gaps in the epidemiology, pathophysiology, diagnosis, and management of NAFLD in PWH and highlight priorities for research.
引用
- Lake JE, Overton T, Naggie S, et al. Expert Panel Review on Nonalcoholic Fatty Liver Disease in Persons With Human Immunodeficiency Virus. Clin Gastroenterol Hepatol. 2020. PMID: 33069882. doi:10.1016/j.cgh.2020.10.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。